{"id":"menactra-tm","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"10-15","effect":"Injection site erythema"},{"rate":"8-12","effect":"Injection site swelling"},{"rate":"30-35","effect":"Headache"},{"rate":"25-30","effect":"Fatigue"},{"rate":"20-25","effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide capsules from four meningococcal serogroups conjugated to diphtheria toxoid as a carrier protein. This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in robust antibody production and immunological memory against these pathogenic meningococcal strains.","oneSentence":"Menactra is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against serogroups A, C, W, and Y of Neisseria meningitidis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:38.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 11 years of age and older"}]},"trialDetails":[{"nctId":"NCT01235975","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-30","conditions":"Infections, Meningococcal","enrollment":400},{"nctId":"NCT00369824","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-26","conditions":"Infections, Papillomavirus","enrollment":1330}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Menactra TM","genericName":"Menactra TM","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Menactra is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against serogroups A, C, W, and Y of Neisseria meningitidis. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 11 years of age and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}